Clinical trial
Irinotecan and Capecitabine in Treating Patients With Solid Tumors
NCT00003867 · Montefiore Medical Center, Other · Completed
Key facts
| NCT number | NCT00003867 |
|---|---|
| Title | Irinotecan and Capecitabine in Treating Patients With Solid Tumors |
| Official title | Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies |
| Lead sponsor | Montefiore Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, irinotecan hydrochloride |
| Enrollment | 30 |
| Start date | Mar 1, 1999 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | Feb 16, 2004 |
| Last update posted | Sep 10, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: